Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen

NCT02569996 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02569996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02569996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2005
Completion date
August 31, 2013
Enrollment
124 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, follicular